Correlation between serum uric acid and catecholamines in college students

doi:10.3969/j.issn.1004-583X.2021.04.014

Abstract

Abstract:

Objective To study the correlation between serum uric acid(SUA) level and catecholamines, blood pressure in college students. Methods A total of 285 from 5 185 college students who participated in the blood pressure survey were selected by using R language stratified random sampling method. According to SUA level, college students were divided into non-hyperuricemia group (177 cases) and hyperuricemia group (108 cases). The plasma catecholamine, biochemical and other indicators were tested and compared between two groups. The correlation was analyzed between SUA and plasma epinephrine(E), norepinephrine(NE), dopamine(DA), systolic blood pressure(SBP), diastolic blood pressures(DBP), heart rate(HR), body mass index(BMI), fasting blood glucose(FBG), serum creatinine(SCr), total cholesterol(TC), triglycerides(TG), high-density lipoprotein cholesterol(HDL-C), and low-density lipoprotein cholesterol(LDL-C). Results In female college students, the plasma E in hyperuricemia group was higher than that in non-hyperuricemia group (P<0.05). In the college students, SBP, DBP, BMI, SCr, SUA, TC, TG, LDL-C in hyperuricemia group were higher than those in non-hyperuricemia group, but HDL-C was lower than that in non-hyperuricemia group (all P<0.05). SUA was positively correlated with plasma E in female college students (P<0.05). The SUA level of all participants was positively correlated with SBP, DBP, BMI, SCr, TG, and LDL-C (all P<0.05), but negatively correlated with HDL-C (P<0.05). Conclusion In the college students, hyperuricemia is closely related with hypertension, obesity, dyslipidemia, and elevated SCr, the higher plasma E level and the greater hyperuricemia risk. The correlation is the strongest between the plasma E and SUA in female college students.

Key words: uric acid, epinephrine, students, health surveys

CLC Number:

R589.6

Li Yaru, Zhao Haiying, Ji Xiaoyi, Wang Menglin, Wang Hao, Li Ling, Jiang Ling, Wang Xinyu. Correlation between serum uric acid and catecholamines in college students[J]. Clinical Focus, 2021, 36(4): 357-360.

Add to citation manager EndNote|Ris|BibTeX

URL: https://huicui.hebmu.edu.cn/EN/10.3969/j.issn.1004-583X.2021.04.014

https://huicui.hebmu.edu.cn/EN/Y2021/V36/I4/357

Figures/Tables 2

References 24

[1]	Liu R, Han C, Wu D, et al. Prevalence of hyperuricemia and gout in mainland China from 2000 to 2014: A systematic review and meta-analysis[J]. Biomed Res Int, 2015; 2015:762820.
[2]	Zhu Y, Pandya BJ, Choi HK, et al. Comorbidities of gout and hyperuricemia in the US general population: NHANES 2007-2008[J]. Am J Med, 2012,125(7):679-687. doi: 10.1016/j.amjmed.2011.09.033 URL
[3]	Yonetani Y, Iwaki K. Catecholamine-induced hyperuricemia in eviscerated rats with functional hepatectomy[J]. Jpn J Pharmacol, 1981,31(3):323-332. pmid: 6895530
[4]	Sumi T, Umeda Y. Adrenergic regulation of the plasma levels of purine metabolites in the rat[J]. Eur J Pharmacol, 1977,46(3):243-247. pmid: 590333
[5]	Yonetani Y, Ishii M, Ogawa Y, et al. Stimulation by catecholamine of purine catabolism in rats and chickens[J]. Jpn J Pharmacol, 1979,29(2):211-221. pmid: 43910
[6]	马伊雯. 高尿酸血症与慢性应激的相关机制研究[D]. 上海交通大学, 2019.
[7]	Wang J, Qin T, Chen J, et al. Hyperuricemia and risk of incident hypertension: A systematic review and meta-analysis of observational studies[J]. PLoS One, 2014,9(12):e114259. doi: 10.1371/journal.pone.0114259 URL
[8]	Cheng YB, Li Y. Hyperuricemia: Does it matter for the progression from prehypertension to hypertension?[J]. Hypertension, 2018,71(1):66-67. doi: 10.1161/HYPERTENSIONAHA.117.10443 URL
[9]	Kuwabara M, Kuwabara R, Hisatome I, et al. “Metabolically healthy” obesity and hyperuricemia increase risk for hypertension and diabetes: 5-year Japanese cohort study[J]. Obesity (Silver Spring), 2017,25(11):1997-2008. doi: 10.1002/oby.v25.11 URL
[10]	王文, 张维忠, 孙宁玲, 等. 中国血压测量指南[J]. 中华高血压杂志, 2011, 19(12):1101-1115+1100.
[11]	刘力生. 中国高血压防治指南2010[J]. 中华高血压杂志, 2011,19(8):701-743.
[12]	Wu X, Jian G, Tang Y, et al. Asymptomatic hyperuricemia and incident congestive heart failure in elderly patients without comorbidities[J]. Nutr Metab Cardiovasc Dis, 2019,30(4) : 666-673. doi: 10.1016/j.numecd.2019.12.008 URL
[13]	Mazzali M, Hughes J, Kim YG, et al. Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism[J]. Hypertension, 2001,38(5):1101-1106. pmid: 11711505
[14]	Krishnan E, Pandya BJ, Chung L, et al. Hyperuricemia in young adults and risk of insulin resistance, prediabetes, and diabetes: A 15-year follow-up study[J]. Am J Epidemiol, 2012,176(2):108-116. doi: 10.1093/aje/kws002 URL
[15]	Han T, Lan L, Qu R, et al. Temporal relationship between hyperuricemia and insulin resistance and its impact on future risk of hypertension[J]. Hypertension, 2017,70(4):703-711. doi: 10.1161/HYPERTENSIONAHA.117.09508 URL
[16]	Takagi M, Tanaka Y, Yamasaki Y, et al. Responsiveness of insulin-induced cardiac sympathetic nerve activation associates with blood pressure regulation in diabetics[J]. Am J Physiol Endocrinol Metab, 2003,284(5):E1022-1026. doi: 10.1152/ajpendo.00169.2002 URL
[17]	Katz JL, Weiner H. Psychosomatic considerations in hyperuricemia and gout[J]. Psychosom Med, 1972,34(2):165-182. pmid: 4552779
[18]	Ji C, Li Y, Cui L, et al. Prenatal earthquake exposure and midlife uric acid levels among Chinese adults[J]. Arthritis Care Res (Hoboken), 2017,69(5):703-708. doi: 10.1002/acr.22973 URL
[19]	凌喜凤, 杨蓉. 铁路机车司机血糖与血尿酸的调查研究[J]. 职业卫生与病伤, 2002,17(3):185-186.
[20]	Lin X, Wang X, Li X, et al. Gender- and age-specific differences in the association of hyperuricemia and hypertension: A cross-sectional study[J]. Int J Endocrinol, 2019: 7545137.
[21]	Kim IY, Han K, Kim DH, et al. Women with metabolic syndrome and general obesity are at a higher risk for significant hyperuricemia compared to men[J]. J Clin Med, 2019,8(6):837. doi: 10.3390/jcm8060837 URL
[22]	王钒, 赵永强, 栾夏青, 等. 廊坊市3820例体检人群高尿酸血症检出情况及影响因素分析[J]. 实用预防医学, 2020,27(6):715-717.
[23]	谭嘉莉, 郑珊珊, 陈红虹, 等. 佛山市体检人群高尿酸血症患病现况及相关危险因素分析[J]. 实用预防医学, 2019,26(7):844-846.
[24]	周薇, 单年春, 谭英, 等. 医务工作者高脂血症与高尿酸血症关系的纵向研究[J]. 中华健康管理学杂志, 2018,12(3):252-258.

变量	总人群		男性		女性
变量	非高尿酸血症组 (n=177)	高尿酸血症组 (n=108)	非高尿酸血症组 (n=73)	高尿酸血症组 (n=65)	非高尿酸血症组 (n=104)	高尿酸血症组 (n=43)
SBP(mmHg)	126(113.00-138.33)	140(127-154)^a	130(119-140)	140.5(129-160)^a	123.71±17.14	135.11±17.27^a
DBP(mmHg)	72(65-80)	77.5(70-84)^a	73(67.0-80.5)	78.7(70-84)	71.50±11.26	77.13±10.64^a
HR(次/min)	80(71-90)	78.5(71-91)	79(68-89)	75(69-90)	81(72.5-91.0)	82(76.5-99.5)
BMI(kg/m²)	20.7(18.1-23.9)	24.85(22.31-28.37)^a	21.8(18.34-24.10)	24.5(22.1-28.1)^a	20.55(18.06-22.85)	25.04(23.23-28.62)^a
FBG(mmol/L)	4.49(4.26-4.72)	4.615(4.28-4.76)	4.56±0.37	4.55±0.34	4.48(4.26-4.69)	4.66(4.29-4.78)
SCr(μmol/L)	56(49-67)	66(57.0-74.5)^a	69.60±7.51	73.68±9.03^a	50(47.0-54.5)	55(50.5-62.0)^a
SUA(μmol/L)	323(272-357)	466(399.5-538.0)^a	362(333-391)	500(458-578)^a	284.5(248-318)	384(371.5-444.5)^a
TC(mmol/L)	4.1(3.72-4.59)	4.285(3.89-4.87)^a	4.01(3.61-4.56)	4.15(3.84-4.74)^a	4.15(3.85-4.64)	4.61(4.04-5.02)^a
TG(mmol/L)	1.01(0.81-1.31)	1.3(0.85-1.74)^a	1.1(0.83-1.38)	1.25(0.85-1.69)	0.995(0.77-1.26)	1.38(0.84-1.8)^a
HDL-C(mmol/L)	1.43(1.24-1.60)	1.27(1.12-1.49)^a	1.35(1.17-1.45)	1.22(1.07-1.34)^a	1.5(1.32-1.69)	1.34(1.17-1.57)^a
LDL-C(mmol/L)	2.03(1.78-2.43)	2.395(1.995-2.765)^a	2.04(1.79-2.45)	2.26(1.94-2.65)^a	2.03(1.76-2.43)	2.49(2.07-2.82)^a
DA(pg/ml)	67.37(48.70-108.32)	70.73(44.84-153.48)	82.5(59.89-114.84)	82.32(49.79-152.52)	66.50(43.83-94.84)	54.74(33.96-154.11)
E(pg/ml)	16.9(3.65-59.75)	37.39(6.25-68.89)	16.7(3.76-64.23)	33.87(5.93-33.89)	18.26(3.65-53.35)	54.13(32.02-79.80)^a
NE(pg/ml)	30.34(13.58-52.17)	29.76(19.56-62.16)	31.91(22.67-48.97)	44.43(21.80-86.90)	23.56(10.46-54.42)	28.8(16.48-39.35)

变量	总人群		男性		女性
变量	非高尿酸血症组 (n=177)	高尿酸血症组 (n=108)	非高尿酸血症组 (n=73)	高尿酸血症组 (n=65)	非高尿酸血症组 (n=104)	高尿酸血症组 (n=43)
SBP(mmHg)	126(113.00-138.33)	140(127-154)^a	130(119-140)	140.5(129-160)^a	123.71±17.14	135.11±17.27^a
DBP(mmHg)	72(65-80)	77.5(70-84)^a	73(67.0-80.5)	78.7(70-84)	71.50±11.26	77.13±10.64^a
HR(次/min)	80(71-90)	78.5(71-91)	79(68-89)	75(69-90)	81(72.5-91.0)	82(76.5-99.5)
BMI(kg/m²)	20.7(18.1-23.9)	24.85(22.31-28.37)^a	21.8(18.34-24.10)	24.5(22.1-28.1)^a	20.55(18.06-22.85)	25.04(23.23-28.62)^a
FBG(mmol/L)	4.49(4.26-4.72)	4.615(4.28-4.76)	4.56±0.37	4.55±0.34	4.48(4.26-4.69)	4.66(4.29-4.78)
SCr(μmol/L)	56(49-67)	66(57.0-74.5)^a	69.60±7.51	73.68±9.03^a	50(47.0-54.5)	55(50.5-62.0)^a
SUA(μmol/L)	323(272-357)	466(399.5-538.0)^a	362(333-391)	500(458-578)^a	284.5(248-318)	384(371.5-444.5)^a
TC(mmol/L)	4.1(3.72-4.59)	4.285(3.89-4.87)^a	4.01(3.61-4.56)	4.15(3.84-4.74)^a	4.15(3.85-4.64)	4.61(4.04-5.02)^a
TG(mmol/L)	1.01(0.81-1.31)	1.3(0.85-1.74)^a	1.1(0.83-1.38)	1.25(0.85-1.69)	0.995(0.77-1.26)	1.38(0.84-1.8)^a
HDL-C(mmol/L)	1.43(1.24-1.60)	1.27(1.12-1.49)^a	1.35(1.17-1.45)	1.22(1.07-1.34)^a	1.5(1.32-1.69)	1.34(1.17-1.57)^a
LDL-C(mmol/L)	2.03(1.78-2.43)	2.395(1.995-2.765)^a	2.04(1.79-2.45)	2.26(1.94-2.65)^a	2.03(1.76-2.43)	2.49(2.07-2.82)^a
DA(pg/ml)	67.37(48.70-108.32)	70.73(44.84-153.48)	82.5(59.89-114.84)	82.32(49.79-152.52)	66.50(43.83-94.84)	54.74(33.96-154.11)
E(pg/ml)	16.9(3.65-59.75)	37.39(6.25-68.89)	16.7(3.76-64.23)	33.87(5.93-33.89)	18.26(3.65-53.35)	54.13(32.02-79.80)^a
NE(pg/ml)	30.34(13.58-52.17)	29.76(19.56-62.16)	31.91(22.67-48.97)	44.43(21.80-86.90)	23.56(10.46-54.42)	28.8(16.48-39.35)

变量	总人群		男性		女性
变量	r值	P值	r值	P值	r值	P值
SBP	0.354	<0.01	0.317	<0.01	0.22	0.007
DBP	0.215	<0.01	0.21	0.013	0.159	0.054
HR	-0.04	0.505	0.017	0.846	0.038	0.644
BMI	0.415	<0.01	0.355	<0.01	0.544	<0.01
FBG	0.078	0.191	-0.008	0.925	0.103	0.214
SCr	0.64	<0.01	0.244	0.004	0.545	<0.01
TC	0.096	0.106	0.208	0.014	0.239	0.004
TG	0.235	<0.01	0.179	0.036	0.334	<0.01
HDL-C	-0.413	<0.01	-0.263	0.002	-0.327	<0.01
LDL-C	0.266	<0.01	0.294	<0.01	0.343	<0.01
DA	0.092	0.327	0.079	0.564	-0.134	0.313
E	0.086	0.321	0.043	0.720	0.263	0.037
NE	0.171	0.084	0.151	0.289	0.103	0.467

变量	总人群		男性		女性
变量	r值	P值	r值	P值	r值	P值
SBP	0.354	<0.01	0.317	<0.01	0.22	0.007
DBP	0.215	<0.01	0.21	0.013	0.159	0.054
HR	-0.04	0.505	0.017	0.846	0.038	0.644
BMI	0.415	<0.01	0.355	<0.01	0.544	<0.01
FBG	0.078	0.191	-0.008	0.925	0.103	0.214
SCr	0.64	<0.01	0.244	0.004	0.545	<0.01
TC	0.096	0.106	0.208	0.014	0.239	0.004
TG	0.235	<0.01	0.179	0.036	0.334	<0.01
HDL-C	-0.413	<0.01	-0.263	0.002	-0.327	<0.01
LDL-C	0.266	<0.01	0.294	<0.01	0.343	<0.01
DA	0.092	0.327	0.079	0.564	-0.134	0.313
E	0.086	0.321	0.043	0.720	0.263	0.037
NE	0.171	0.084	0.151	0.289	0.103	0.467